Slide 1: Exchange filing cover letter under Regulation 30
Communication Address: Solara Active Pharma Sciences Limited Batra Centre No. 28. Sardar Patel Road. Post Box 2630 Guindy. Chennai - 600 032. India Tel : +91 44 43446700. 22207500 Fax : +91 44 22350278 E-mail : investors@solara.com www.solara.co.in April 11, 2021 The BSE Limited The National Stock E
Slide 2: Accelerating Growth: Solara and Aurore Merge to Become India's Second Largest Pure Play API / CRAMS Company
ACCELERATING GROWTH: SOLARA AND AURORE MERGE TO BECOME INDIA’S SECOND LARGEST PURE PLAY API / CRAMS COMPANY STRONG FOUNDATION. ACCELERATING GROWTH.
Slide 3: Safe Harbor
Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "p
Slide 4: A progressive move to combine two growth engines and build a future ready platform
A progressive move to combine two growth engines and build a future ready platform Rajender Rao Juvvadi Founder and MD, Aurore “As Solara continues its journey towards accelerated growth, the combination with Aurore is a significant boost. The two entities complement each other on product portfolio,
Slide 5: Accelerating to become India's second largest pure-play API/CRAMS Company
Accelerating to become India’s second largest pure-play API/CRAMS Company K E Y T R A N S A C T I O N D E TA I L S DEAL METRICS ► Aurore to merge with Solara in an all-stock transaction and the shareholders of Aurore will have 27% ownership in the Solara Particulars Pre-transaction New issue post-tr
Slide 6: Aurore's strategic capabilities are highly complementary to Solara's growth model
Aurore’s strategic capabilities are highly complementary to Solara’s growth model BACKGROUND EXPERIENCE PHILOSOPHY CAPACITY R&D CAPABILITY • Aurore Group consists of • Formed as a partnership • The leadership team at • Two facilities in India with • Dedicated center in Aurore Life Sciences between R
Slide 7: Strategic Rationale: Better financial outcomes with significant asset synergies
Strategic Rationale: Better financial outcomes with significant asset synergies Robust balance sheet provides opportunities for sizeable investments • Combination is Margin and EPS accretive. • Assets turn at Aurore is ~2x and that of the merged entity increases from 1.5x to ~1.7x 1 Strengthened • R
Slide 8: Strategic Rationale: Bolstered CRAMS presence with increased product mix and R&D velocity
Strategic Rationale: Bolstered CRAMS presence with increased product mix and R&D velocity CRAMS business triples in revenue from the addition of Aurore’s CRAMS portfolio • The nascent CRAMS business of Solara is ~INR 75 Cr. and benefits from significant addition of Aurore’s CRAMS revenue of ~INR 150
Slide 9: Strategic Rationale: A wider push to customers with a strengthened APAC presence
Strategic Rationale: A wider push to customers with a strengthened APAC presence Improved product portfolio will enable Solara to grow further with its marquee customers • Solara and Aurore’s customers will benefit from the combination which offers sizeable cross selling opportunities • Increased pr
Slide 10: Strategic Rationale: Enhanced product footprint in the US market
Strategic Rationale: Enhanced product footprint in the US market Solara’s leadership position in the US gets further augmented by strong filings of Aurore 7 • Aurore has filed 20 DMFs for US market. These products are complementary to Solara’s existing filings US presence • 4 DMFs have been triggere
Slide 11: Transaction Summary
Transaction Summary: TYPE TIMELINE POST TRANSACTION LANDSCAPE • Aurore to merge with Solara in an all- • Subject to statutory, regulatory, • Post the deal, the company shall stock transaction creditors and shareholder approvals operate as Solara • Aurore shareholders will own 27% of the • Deal Effec
Slide 12: Corporate and registered office
CORPORATE OFFICE REGISTERED OFFICE 3rd & 4th Floor, Batra Centre, No.28, 201, Devavrata, Sector 17, Sardar Patel Road, Guindy, Chennai - 600 032 Vashi, Navi Mumbai - 400 703. Tel.: +91 44 4344 6700 / 2220 7500 Tel.: +91 22 2789 2924 Fax No. +91 22 2789 2942 Fax No.: +91 44 2235 0278 Email: investors